Regenxbio announced Thursday that its gene therapy for Duchenne muscular dystrophy achieved its primary endpoint in a pivotal study, clearing a path toward regulatory submission. The company now targets a Biologics License Application with the FDA by 2027.

This positions the firm to become the second entrant in a market where Sarepta Therapeutics' Elevidys already holds approval. Duchenne affects roughly one in every 3,500 male births, causing progressive muscle degeneration and premature death.

The biotech has not disclosed specific efficacy data or statistical details from the trial. Executives declined to provide sample sizes or effect magnitudes, citing ongoing analyses and planned presentations at upcoming medical conferences.

If approved, Regenxbio's therapy could offer an alternative mechanism of action, potentially expanding treatment options for patients who cannot tolerate or fail to respond to existing therapies. The company must now navigate manufacturing scale-up and pricing negotiations.

Analysts caution that regulatory hurdles remain, particularly around long-term safety data and durability of effect, which the FDA will scrutinize closely during the review process.